Sequenom : Laboratories To Present At ACMG Meeting

SAN DIEGO, March 24, 2015 /PRNewswire / -- Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today that it will be presenting six scientific posters on noninvasive prenatal testing (NIPT) and supporting a continuing medical education (CME) satellite symposia on next-generation consent for prenatal testing at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting through an unrestricted educational grant, which will be held March 24-28, 2015 in Salt Lake City, Utah.

Sequenom Laboratories Scientific Posters at ACMG
Thursday, March 26, 10:30am - 12pm and Friday, March 27, 10:30am - 12pm
Salt Palace Convention Center, Room: Exhibit Hall ABC

• Poster #354: Updated clinical experience of trisomy 16 and 22 microdeletion detection by noninvasive prenatal testing (NIPT).
• Poster #428: Automated genomic interpretation of sub-chromosomal fetal copy number variation by sequencing circulating cell-free DNA from maternal plasma.
• Poster #681: Clinical experience at Newton-Wellesley Hospital.
• Poster #683: Rings and things: Noninvasive prenatal testing's unique view of the biology and embryology behind chromosomal ring formation and segregation.
• Poster #694: Two cases of Wolf-Hirschhorn syndrome detected by noninvasive prenatal testing (NIPT).
• Poster #708: Noninvasive prenatal testing aids in detecting parental balanced translocation and highlights limitations of karyotype.

The posters showcase recent research and clinical applications associated with the MaterniT21® PLUS NIPT technology.

"The Next-Gen Informed Consent for Prenatal Testing" CME-Educational Session
Friday, March 27, 7:15 am-8:45 am at the Salt Palace Convention Center
This continuing medical education event will explore the principles of informed consent and the challenges of its application in the busy prenatal practice. It will include an overview of key issues in NIPT consenting and of models that may meet the needs of patients, providers, and laboratories. The session is accessible by registered ACMG attendees only.

In recent company news, Sequenom Laboratories, in partnership with Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, announced the launch of the HerediT® UNIVERSAL carrier screening test as a service to ordering physicians. The HerediT UNIVERSAL test screens for more than 250 genetic disorders by analyzing over 2,000 genetic mutations. Current options are limited to single gene testing or tests that can identify approximately 100 hereditary conditions. The HerediT UNIVERSAL test can be performed preconception or at any time during pregnancy.

More information about the HerediT UNIVERSAL and MaterniT21 PLUS tests will be available at Sequenom Laboratories' booth #805.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, MaterniT21® PLUS, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. To learn how Sequenom Laboratories is interpreting the genome for improving the lives of patients everywhere, visitwww.laboratories.sequenom.com and follow @SequenomLabs and #ACMGMtg.

SEQUENOM®, Sequenom Laboratories™, HerediT®, MaterniT21® PLUS, SensiGene® and VisibiliT™, are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of innovative products and services and what models of informed consent may meet the needs of patients, providers, and laboratories. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.